Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Ma, Cynthia X., Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric Winer, et al. “Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer..” Clin Cancer Res 23, no. 19 (October 1, 2017): 5687–95. https://doi.org/10.1158/1078-0432.CCR-17-0900.

PMID
28679771
Full Text

Blackwell, K., P. Gascon, C. M. Jones, A. Nixon, A. Krendyukov, R. Nakov, Y. Li, and N. Harbeck. “Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer..” Ann Oncol 28, no. 9 (September 1, 2017): 2272–77. https://doi.org/10.1093/annonc/mdx303.

PMID
28637287
Full Text

Harbeck, Nadia, Pere Gascon, Clyde M. Jones, Allen Nixon, Andriy Krendyukov, Roumen Nakov, Yuhan Li, and Kimberly Blackwell. “Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials..” Future Oncol 13, no. 16 (July 2017): 1385–93. https://doi.org/10.2217/fon-2017-0041.

PMID
28453299
Full Text

Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, et al. “Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial..” Lancet Oncol 18, no. 6 (June 2017): 732–42. https://doi.org/10.1016/S1470-2045(17)30312-1.

PMID
28526536
Full Text

Musolino, Antonino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortes, Kimberly Blackwell, et al. “Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy..” Breast Cancer Res 19, no. 1 (February 10, 2017). https://doi.org/10.1186/s13058-017-0807-8.

PMID
28183331
Full Text

Sammons, Sarah L., Donna L. Topping, and Kimberly L. Blackwell. “HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles..” Curr Cancer Drug Targets 17, no. 7 (2017): 637–49. https://doi.org/10.2174/1568009617666170330120452.

PMID
28359238
Full Text

Anderson, Grace R., Suzanne E. Wardell, Merve Cakir, Lorin Crawford, Jim C. Leeds, Daniel P. Nussbaum, Pallavi S. Shankar, et al. “PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation..” Sci Transl Med 8, no. 369 (December 14, 2016). https://doi.org/10.1126/scitranslmed.aae0348.

PMID
27974663
Full Text

Mitri, Zahi, Rita Nanda, Kimberly Blackwell, Colleen M. Costelloe, Ilona Hood, Caimiao Wei, Abenaa M. Brewster, et al. “TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis..” Clin Cancer Res 22, no. 23 (December 1, 2016): 5706–12. https://doi.org/10.1158/1078-0432.CCR-15-2845.

PMID
27166393
Full Text

Hortobagyi, Gabriel N., Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Shani Paluch-Shimon, Mario Campone, et al. “Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer..” N Engl J Med 375, no. 18 (November 3, 2016): 1738–48. https://doi.org/10.1056/NEJMoa1609709.

PMID
27717303
Full Text

Farber, S Harrison, Vadim Tsvankin, Jessica L. Narloch, Grace J. Kim, April K. S. Salama, Gordana Vlahovic, Kimberly L. Blackwell, John P. Kirkpatrick, and Peter E. Fecci. “Embracing rejection: Immunologic trends in brain metastasis..” Oncoimmunology 5, no. 7 (July 2016). https://doi.org/10.1080/2162402X.2016.1172153.

PMID
27622023
Full Text

Pages